|
This document is a final report on a 96-hour static-renewal acute toxicity test of Perfluorooctanesulfonate (PFOS) conducted with the sheepshead minnow, submitted by Wildlife International, Ltd. to 3M Corporation, and completed in compliance with Good Laboratory Practice Standards.
|
2001 |
AR226-1051
|
v1MD5exEyoo1YLa7Lxz72a1g6 |
46 |
|
The document details an acute toxicity study of Perfluorooctanesulfonate (PFOS) on juvenile rainbow trout (Oncorhynchus mykiss), conducted under GLP conditions, which aimed to determine the LC50 values after a 96-hour exposure to various concentrations of PFOS sourced from a 3M lot.
|
2001 |
AR226-1051
|
B500ZapxbjD7pp4QLpbGL723m |
4 |
|
The document reports on an acute toxicity study of Perfluorooctanesulfonate (PFOS) conducted on juvenile sheepshead minnows, indicating a purity of 86.9% and detailing the testing methodology and conditions used to assess the substance's impact on aquatic life.
|
2001 |
AR226-1051
|
91M7R3QpV9b4gRwpY61em8VyL |
5 |
|
The document is an analytical report from 3M Environmental Laboratory detailing the presence and concentration of PFOS, M556, PFOSAA, and PFOSA in the liver and sera of rats exposed to EtFOSE-OH, completed on May 31, 2001.
|
2001 |
AR226-1051
|
mmqb65xg2vrmqgyonj9z0XY9O |
143 |
|
The document reports on a 104-week dietary carcinogenicity study conducted by 3M, analyzing the presence and concentration of PFOS and related compounds in serum and liver samples of rats exposed to N-Ethyl Perfluorooctanesulfonamido Ethanol.
|
2001 |
AR226-1051
|
EmYB08qYzJGm0VRn0Xy05Empb |
212 |
|
The document reports on a 104-week dietary carcinogenicity study conducted by 3M, analyzing the presence and concentration of PFOS and related compounds in serum and liver samples of rats exposed to N-Ethyl Perfluorooctanesulfonamido Ethanol, completed on June 6, 2001.
|
2001 |
AR226-1051
|
OzZy6142RXEEkJJed8ke6LKjM |
310 |
|
The document is a final report on a mortality study conducted by the University of Minnesota, which found no significant association between occupational exposure to perfluorooctanoic acid (PFOA) at the 3M Cottage Grove facility and overall cancer mortality, although a modest increased risk of death from cerebrovascular disease was observed in workers with definite PFOA exposure.
|
2001 |
AR226-1030
|
e7DYb8rvRgq7EaKem5bVxmKLq |
28 |
|
The document discusses a study by 3M Company analyzing health outcomes of employees at the Decatur Chemical and Film Plant from 1993 to 1998, emphasizing the use of administrative databases for morbidity research related to potential health impacts from exposure to perfluorinated compounds.
|
2001 |
AR226-1030
|
Dd3Veqrm2rLza9aJ9G6Yyy1rN |
134 |
|
The document is a final report on a 4-week capsule toxicity study of Ammonium Perfluorooctanoate (APFO) conducted on Cynomolgus monkeys by Covance Laboratories, sponsored by the APME Ad-Hoc APFO Toxicology Working Group, and completed on December 18, 2001, with compliance to EPA Good Laboratory Practice Standards noted.
|
2001 |
AR226-1051
|
2NJQaKJgeb9VgjdG2yNoa5ep6 |
159 |
|
The document is a final report on a mortality study conducted by Bruce H. Alexander, PhD, which investigates the relationship between occupational exposure to perfluorooctanesulfonyl fluoride (POSF) based fluorochemicals and mortality among employees at the 3M facility in Decatur, Alabama, finding lower overall mortality rates than expected but elevated risks for bladder cancer among high-exposed workers
|
2001 |
AR226-1030
|
5DxRygmvb7QJV3Nn9EpZxjjbV |
32 |
|
The document is a final report from 3M Company detailing a study on serum levels of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and perfluorohexanesulfonate (PFHS) among 45 employees engaged in fluorochemical research, revealing geometric mean serum levels of 0.116 ppm for PFOS
|
2001 |
AR226-1030
|
MJMXpgLqneOpzr1OMM6L8jNjx |
6 |
|
The document reports on a study conducted by 3M Company measuring serum levels of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) among 258 employees at the Antwerp chemical plant, finding geometric mean levels of 0.44 ppm for PFOS and 0.33 ppm for PFOA, with higher exposure levels
|
2001 |
AR226-1030
|
X81Nv74epabwLMDpe5oY1dzpd |
39 |
|
The report from 3M Company details a medical surveillance program conducted in 2000, revealing that serum levels of perfluorooctanoate (PFOA) among Decatur chemical plant employees increased to a geometric mean of 1.13 ppm, particularly among cell operators, while perfluorooctanesulfonate (PFOS) levels remained stable compared to 1998
|
2001 |
AR226-1030
|
oyorJmRzK6ak7MXD41ZQYZ0w |
36 |
|
The document is a final report from 3M Company detailing a study on the identification of perfluorooctanesulfonate (PFOS) in human tissue, which found that average serum levels in non-occupationally exposed humans were significantly lower than those observed in cynomolgus monkeys during a feeding study.
|
2001 |
AR226-1030
|
DdXvnJqQbQyrRBB1mzox2JDgB |
35 |
|
This interim report from 3M Company details a study on the distribution of perfluorooctanesulfonate (PFOS) in serum samples from over 600 adult blood donors in the United States, aiming to characterize the presence of fluorochemicals in the general population.
|
2001 |
AR226-1030
|
rpKRnD04B1nkxdveLv41Zqe9e |
5 |
|
This interim report from 3M Company details a study on the identification of perfluorooctanesulfonate (PFOS) and other fluorochemicals in serum samples from 599 children aged 2 to 12 in the United States, aiming to characterize the distribution of these substances in the population.
|
2001 |
AR226-1030
|
EvYy6gOnLJJqqw4LvQ98o5EBb |
5 |
|
3M submitted a supplemental toxicokinetic study of perfluorooctane sulfonamide (PFOSA) to the EPA as part of their ongoing dialogue regarding fluorochemistry and to fulfill a previous omission from their data submissions.
|
2001 |
AR226-1030
|
61pMLpvzBQn3DNjY0QvYdgGm |
22 |
|
3M reported on April 25, 2001, that their ongoing study of the serum half-life of perfluorooctane sulfonate (PFOS) in retired workers revealed a mean half-life of 303 days based on data from 18 of 27 employees, which is an improvement over previous estimates but cautioned that the data are difficult to interpret.
|
2001 |
AR226-1030
|
LpeJp9n1omajEwNv3QM0KZr35 |
2 |
|
The document is a summary of analytical results for perfluorinated compounds, including PFOA and PFOS, from samples drawn in 1995, indicating various concentrations detected in blood samples.
|
2001 |
AR226-1030
|
4Qb5bBMdBZna9vb4ZY5OKw3Lx |
2 |
|
3M submitted acute toxicity test results for perfluorooctane sulfonate (PFOS) on honey bees, indicating a contact LD50 of 59.7 mg/Kg (moderately toxic) and an oral LD50 of 5 mg/Kg (highly toxic), while asserting that environmental exposure levels are unlikely to reach these toxicity levels.
|
2001 |
AR226-1030
|
gaGXBkbzg0eb5qLEYpmbYQ5DN |
2 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding a two-year dietary study of potassium perfluorooctanesulfonate (PFOS) in rats, indicating that preliminary statistical findings suggest potential risks that will be further evaluated in the final report.
|
2001 |
AR226-1030
|
G6OvYop2O9vE1v1GLooxMzzym |
2 |
|
3M is supplementing its previous notice to the EPA regarding a two-year dietary study of N-ethyl perfluorooctanesulfonamidoethanol (N-EtFOSE) in rats, highlighting statistically significant increases in thyroid follicular-cell tumors in male rats, with a final report forthcoming.
|
2001 |
AR226-1030
|
XO1Nq61ZkgjOdg2yEO8JNRxX4 |
2 |
|
3M submitted a supplemental report to the EPA detailing preliminary findings from a study on perfluorooctane sulfonate (PFOS) that investigates its potential toxicity and effects on perinatal mortality in rats, including a focus on cholesterol synthesis and serum lipid levels.
|
2001 |
AR226-1030
|
Q2Gy8vEx64yVEK1Jdxd2g96R |
5 |
|
The document is a final report on a 4-week capsule toxicity study of Ammonium Perfluorooctanoate (APFO) conducted on Cynomolgus monkeys by Covance Laboratories, sponsored by the APME Ad-Hoc APFO Toxicology Working Group, which adhered to EPA Good Laboratory Practice Standards with some exceptions.
|
2001 |
AR226-1052
|
2rpV743jBkn3km3N5B567xMN |
159 |
|
This document is a final report on a 26-week capsule toxicity study of Ammonium Perfluorooctanoate (APFO) conducted on Cynomolgus monkeys by Covance Laboratories, sponsored by 3M, which adhered to EPA Good Laboratory Practice Standards with some exceptions noted.
|
2001 |
AR226-1051
|
qd6eY9aBRBkryNbmXx6rDZj4n |
463 |
|
The document is an analytical report from 3M Environmental Laboratory detailing a 26-week toxicity study of Ammonium Perfluorooctanoate (APFO) in cynomolgus monkeys, focusing on the presence and concentration of perfluorooctanoate in various biological samples, conducted in compliance with EPA Good Laboratory Practice standards.
|
2001 |
AR226-1051
|
3QK89gmzjBY5jBJbR1JVV410E |
411 |
|
The document reports on a study conducted by 3M Company to assess the acute oral toxicity of a material identified as T-2001CoC in male and female albino rats, finding an LD50 between 0.5 ml/kg and 2.5 ml/kg, with significant effects observed at higher dosage levels.
|
2001 |
AR226-0217
|
daxp3rd61moN2aZ67526bw5a9 |
2 |
|
The document reports on a primary eye irritation study conducted by 3M Company on a test material (T-2001CoC) using albino rabbits, concluding that the material is not a primary ocular irritant but requires cautionary labeling.
|
2001 |
AR226-0218
|
4aJgwG2Ypkoe6rawoqxz5xoMa |
3 |
|
The document details a primary skin irritation study conducted by 3M Company on a material related to PFOA, using albino rabbits to assess the degree of irritation caused by the substance when applied to intact and abraded skin.
|
2001 |
AR226-0219
|
wg7Kw9rXzeVMXKG0nxROdQ4GQ |
3 |
|
The document is a final report on a 26-week capsule toxicity study of Ammonium Perfluorooctanoate (APFO) conducted in Cynomolgus monkeys by Covance Laboratories, sponsored by 3M, which complies with EPA Good Laboratory Practice Standards except for certain determinations performed by the University of Dundee.
|
2001 |
AR226-1052
|
5kx8p9gNpX1x8dL3qM9oJ6r4D |
463 |
|
The document reports on a 26-week toxicity study of Ammonium Perfluorooctanoate (APFO) conducted by 3M Environmental Laboratory on Cynomolgus monkeys, detailing the presence and concentration of perfluorooctanoate in various biological samples, while noting some exceptions to Good Laboratory Practice compliance.
|
2001 |
AR226-1052
|
gDNjeo1gjopdaY612bB61LRqN |
411 |
|
The document is an analytical report from 3M Environmental Laboratory detailing a 104-week dietary carcinogenicity study on rats, which measured the presence and concentration of PFOS and related compounds in serum and liver samples after exposure to N-Ethyl Perfluorooctanesulfonamido Ethanol.
|
2001 |
AR226-1068
|
5kjGjLZ8R999MgvEvpLjG5zV |
310 |
|
The document is an analytical report from the 3M Environmental Laboratory detailing the presence and concentration of PFOS, PFOSA, PFOSAA, EtFOSE-OH, M556, and PFOSEA in serum and liver samples from rats exposed to N-Ethyl Perfluorooctanesulfonamido Ethanol as part of a 104-week dietary carcinogenicity study.
|
2001 |
AR226-1068
|
jmyMy67DgDJ938d6LVeGprJYO |
212 |
|
3M is on track with its phase-out plan for certain PFOS derivatives, having ceased production in multiple categories as of December 31, 2000, while also meeting reduced production goals for extended use categories.
|
2001 |
AR226-0997
|
qmKYM2E5OjnLbGG01vL63Vodj |
1 |
|
Unreadable document.
|
2001 |
AR226-1001
|
82bnKkrXnQ0z9aB0G89npYg7o |
2 |
|
DuPont's January 25, 2001 letter to the EPA reports the results of blood serum tests for Ammonium Perfluorooctanoate (APFO) among workers, revealing a maximum concentration of 9.0 ppm and a mean concentration of 1.53 ppm, with an investigation ongoing into elevated levels found in a specific job group.
|
2001 |
AR226-1000
|
Gmk4eEvRREgxKGNJ91Q1x7NbV |
14 |
|
The document is a correspondence from the EPA requesting DuPont Haskell Laboratory to provide the complete data set of blood concentrations related to Ammonium Perfluorooctanoate (AFPO) as summarized in their report.
|
2001 |
AR226-1003
|
pe1q28jEvRoQNNaXvL5OGK38j |
1 |
|
The document is a note summarizing a meeting held on January 4, 2001, between the EPA and the Department of Defense regarding alternatives to PFOS-based Aqueous Film Forming Foam (AFFF) and potential plans for transitioning away from its use.
|
2001 |
AR226-1004
|
ZJmneQpZx95801jn5ReoVL050 |
2 |
|
The document summarizes a presentation by toxicologist Rich Purdy to the EPA on March 26, 2001, discussing the relative toxicity and environmental presence of perfluoroalkanoic acids, specifically highlighting that perfluorooctanoic acid (PFOA) is less bioaccumulative and toxic compared to perfluorooctane sulfonate (PFOS), with low levels
|
2001 |
AR226-1005
|
7OyOYBkk58X7N2ozmGp0Y9mmR |
15 |
|
The document discusses the EPA's substantial data on perfluorooctyl sulfonates (PFOS), specifically related to 3M's "Light Water" AFFF formulations, and outlines the ongoing rulemaking activity regarding a proposed significant new use rule (SNUR) for 90 PFOS chemicals being discontinued by 3M Corporation.
|
2001 |
AR226-1006
|
Z8q10qjkYXvEoGvNQOb52vqO |
2 |
|
The document summarizes a March 7, 2001 meeting between the EPA and the Fluoropolymer Manufacturing Group, where concerns were raised about the discontinuation of ammonium perfluorooctanoate (APFO), a derivative of perfluorooctanoic acid (PFOA), by 3M, and the ongoing toxicology research and regulatory considerations regarding APFO and
|
2001 |
AR226-1007
|
Gzz7v2EJ0GL1322bq938m9rZ7 |
1 |
|
The document is a facsimile transmittal from Allen C. Weidman of The Society of the Plastics Industry, Inc. to the EPA, clarifying the status of submissions related to Confidential Business Information (CBI) and non-CBI presentations concerning PFOA made by the Fluoropolymer Manufacturers Group.
|
2001 |
AR226-1008
|
ybYE9DZ5NjaQVQMV9LkNpe3Y2 |
1 |
|
The Fluoropolymer Manufacturers Group provided the EPA with presentation slides detailing their toxicology program, which includes a bio-monitoring test protocol and discussions on alternatives to fluorinated compounds used in manufacturing.
|
2001 |
AR226-1009
|
Gzr3q0QBG3kMBnnMarXr0GmJ7 |
1 |
|
The document outlines the agenda and objectives of an EPA meeting with the Fluoropolymer Manufacturers Group (FMG) on March 7, 2001, focusing on the toxicology program, mass balance data, and industry commitments regarding the safe use and environmental impact of fluoropolymer processing aids (FPAs), including perfluorooctanoic acid (APFO) and perfluor
|
2001 |
AR226-1010
|
3ekmejp06BVk2ybgOvDMD4eqn |
19 |
|
The document is a note summarizing a meeting held on March 28, 2001, between the EPA and 3M to discuss the status of 3M's testing program, phase-out plan for PFOS, and related OECD activities.
|
2001 |
AR226-1013
|
Y99Vddj6r8d0Ywq4LQgq9KYD |
1 |
|
The Fluoropolymer Manufacturers Group expresses appreciation to the EPA for ongoing discussions regarding fluoropolymers and APFO, providing presentation materials that include both confidential and non-confidential information related to the manufacturing processes and benefits of fluoropolymers.
|
2001 |
AR226-1012
|
6R9wjk1oEJq8ZyYYR0v0bbZX9 |
50 |
|
3M provided an update to the EPA regarding their ongoing study of the serum half-life of perfluorooctane sulfonate (PFOS) in retired workers, indicating that new data from a larger group of 27 employees suggested a half-life of approximately 303 days, which is an improvement over previous estimates but still requires cautious interpretation due to study limitations.
|
2001 |
AR226-1015
|
7MRXLDNOvgd1rLLM6mJokO5be |
2 |
|
3M submitted a TSCA 8(e) notice to the EPA detailing acute toxicity studies on perfluorooctane sulfonate (PFOS) conducted on honey bees, reporting a contact LD50 of 59.7 mg/Kg (moderately toxic) and an oral LD50 of 5 mg/Kg (highly toxic).
|
2001 |
AR226-1016
|
3N7yKN6DbO2VB0GxLyey7wdqn |
1 |
|
3M submitted a TSCA 8(e) Supplemental notice to the EPA detailing analyses of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) in human serum samples from various age groups, revealing specific concentration levels and ranges for these compounds.
|
2001 |
AR226-1019
|
oD0n8jNymbxZ5w0kM079Bajwg |
2 |
|
The document discusses a conference call on March 19, 2001, regarding new findings from a serum half-life study on PFOS conducted by 3M, which indicated a half-life of approximately 303 days among 27 retired employees, an improvement over earlier estimates based on limited data from only 3 workers.
|
2001 |
AR226-1020
|
QpRkJ12Dm5QvZrLEOBgEZM57 |
2 |
|
3M submitted a supplemental notice to the EPA regarding a two-year dietary study of N-ethyl perfluorooctanesulfonamidoethanol (N-EtFOSE), highlighting statistically significant findings of thyroid follicular-cell tumors in male rats, in addition to previously reported hepatocellular adenomas in female rats.
|
2001 |
AR226-1021
|
zQwbmMVZjZOqwMwKVvx61JvBB |
2 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding preliminary findings from a two-year dietary study on potassium perfluorooctanesulfonate (PFOS) in rats, indicating that the data may meet reporting thresholds, while noting that the final report will provide further interpretation of biological significance.
|
2001 |
AR226-1022
|
3JBpq8Jk4qEqd5oKZqXbzYQbn |
2 |
|
This document from DuPont Haskell Laboratory provides a corrected dataset of blood concentrations of ammonium perfluorooctanoate (APFO) in employees, responding to a request from the EPA and highlighting errors found in a previous report.
|
2001 |
AR226-1023
|
Gmn1mEqBxyY43Md1rRp3DoDZ4 |
4 |
|
This document outlines ongoing research protocols by 3M and Johns Hopkins University to identify and analyze levels of various fluorochemicals, including PFOA and PFOS, in the sera of children in the United States, with final reports due in 2001 and 2004.
|
2001 |
AR226-0019
|
1LY025q30LdVKjXRGOk3D9Lo |
4 |
|
3M reported on the ongoing serum half-life study of perfluorooctane sulfonate (PFOS) in retired workers, revealing that the mean serum half-life for 18 of 27 employees was approximately 303 days, which is an improvement over previous estimates but still presents interpretive challenges.
|
2001 |
AR226-1024
|
06g0jJ1GRDK0mMMB4aw3VxwRd |
2 |
|
The document is a letter from the EPA to DuPont Haskell Laboratory requesting clarification on why the results of human blood serum tests for ammonium perfluorooctanoate (PFOA) were submitted as voluntary rather than under TSCA Section 8(e), given potential human health hazard concerns.
|
2001 |
AR226-1025
|
O1aemwdmGdw26qD7193oz7Mvj |
1 |
|
This letter from DuPont Haskell Laboratory responds to an EPA inquiry regarding exposure and health effects related to PFOA, indicating that no adverse health effects have been found among exposed employees, and referencing similar findings from studies by 3M.
|
2001 |
AR226-1026
|
a1e4J1OpVJnggvR8XQQkr8Q59 |
2 |
|
3M submitted a TSCA 8(e) supplemental notice to the EPA correcting chemical descriptions for sulfonate-based and carboxylic-based fluorochemicals, including perfluorooctane sulfonate, based on analyses of individual human sera samples collected in 1995.
|
2001 |
AR226-1027
|
YGam68vJ3757b3wNGy8N8G9Dy |
4 |
|
3M Company is requesting the U.S. EPA to redesignate three studies related to fluorochemicals, including a range finding rat teratology study and two eye irritation studies, to the TSCA Section 8(e) docket, as they supplement previous submissions concerning the health effects of these compounds.
|
2001 |
AR226-1028
|
gbYpoE5Q2GV7794NE69QO7gYL |
2 |
|
3M submitted a TSCA 8(e) Supplemental notice to the EPA reporting completed analyses of sulfonate-based and carboxylic-based fluorochemicals, including perfluorooctane sulfonate, in individual stored human sera.
|
2001 |
AR226-1029
|
wqNRZ98aMjqKgwdekv2eJkjg4 |
3 |
|
3M submitted a compact disc to the EPA containing new and previously unsubmitted studies on perfluorooctane sulfonates and related compounds, as part of their ongoing dialogue regarding fluorochemicals.
|
2001 |
AR226-1030
|
xdy1JYRMqYqK9yB864aKRVb80 |
4 |
|
The document is a letter from the EPA to 3M Company regarding the submission of information on perfluorooctane sulfonates (PFOS) and related compounds, confirming its inclusion in the TSCA Public Docket as part of the administrative record on PFOS.
|
2001 |
AR226-1031
|
RaJJv0RezR80OEpvpnLO9e1xk |
1 |
|
This document appears to be a presentation or informational material from the Fire Fighting Foam Coalition discussing Aqueous Film Forming Foam (AFFF), its types, applications, and market segments, with a focus on its effectiveness in fire suppression and safety.
|
2001 |
AR226-1032
|
r6pOB9awyzdKRd70OpyEmy5pr |
36 |
|
DuPont Chemical Solutions Enterprise submitted sanitized copies of two presentations regarding their Research Programs on PFOA and telomer compounds to the U.S. EPA on September 24, 2001, ensuring that no confidential business information was included.
|
2001 |
AR226-1033
|
jgdbGqzmXbV0Gq5p4oaqmbYB9 |
44 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing final reports and analytical data on sulfonate-based fluorochemicals, specifically detailing blood serum and liver levels of PFOS and related compounds from previous studies.
|
2001 |
AR226-1035
|
mmNoJg7dZXgoDB8e66b13ad1g |
3 |
|
The document is a correspondence from DuPont to the U.S. EPA, providing sanitized copies of two presentations regarding their research programs on perfluorinated compounds, specifically mentioning updates on the DuPont Research Program and Telomer Research Program, both presented on February 21, 2001.
|
2001 |
AR226-1034
|
e5zg18Qj8Y0Dn1ann3jNdrjjm |
26 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing final reports and analytical data on sulfonate-based fluorochemicals, including PFOS, to facilitate access to information related to previous notifications.
|
2001 |
AR226-1037
|
g2DdJ01J7oBDM9zmLv2XLJ8MQ |
9 |
|
3M is submitting final reports and supplemental information related to previous TSCA Section 8(e) notifications regarding sulfonate-based fluorochemicals, including analytical studies on PFOS and its derivatives in blood serum and liver levels from rat studies.
|
2001 |
AR226-1038
|
reqgyBn11y4540pmNKVpwyjJ |
13 |
|
This is a 3M letter addressed to the Section 8(e) Docket Coordinator regarding a TSCA 8(e) Supplemental Notice on sulfonate-based fluorochemicals, listing attached submissions related to previous notifications.
|
2001 |
AR226-1036
|
ppEbgmwOReNLGydvwa9Ev1de6 |
96 |
|
This document outlines a study by 3M to determine the concentration ratios of perfluorooctanesulfonate (PFOS) in human liver, serum, and bile, with the aim of understanding tissue concentrations and their significance, following ethical guidelines for tissue procurement.
|
2001 |
AR226-0021
|
g2e0ew9Yvbaqn9qgQmJJvY74G |
3 |
|
This document is a meeting agenda for a DuPont Telomer meeting scheduled on December 17, 2001, from 1:00 to 3:00 PM, listing participants and their organizations.
|
2001 |
AR226-1041
|
EqY1VpEzX6pXoaBLMeQe7b5k4 |
2 |
|
3M is submitting final reports and supplemental information related to previous TSCA Section 8(e) notifications, including analytical studies on the presence and concentration of PFOS and other sulfonate-based fluorochemicals in the liver and serum of rats exposed to NEtFOSE.
|
2001 |
AR226-1039
|
oKJrkqgL3EqZLMZZ1VypVzbr |
41 |
|
This is a cover page for a Telomer Research Update Meeting scheduled for December 18, 2001, with no analytical content retained in the OCR.
|
2001 |
AR226-1043
|
1Q1wnrmzmQeZb1Z15Omq0emvj |
2 |
|
The document is a status report on the Telomer Research Program related to perfluorinated compounds, summarizing key events and updates on toxicology, environmental fate, and effects as discussed in meetings throughout 2001.
|
2001 |
AR226-1044
|
dQEvBVx10VgaJMmp6Y1ZkONee |
33 |
|
The document is a DuPont Product Stewardship Update discussing various aspects of fluorotelomer products, including their chemical properties, toxicology studies, and environmental effects related to perfluorinated compounds.
|
2001 |
AR226-1042
|
5kqLDKyjD1GyGb2MObwK5oK50 |
35 |
|
3M submitted two studies to the EPA regarding perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) as part of their ongoing dialogue about fluorochemicals, focusing on health effects observed in employees from their medical surveillance programs.
|
2001 |
AR226-1046
|
5bk6Z65EJXvy8gb4wa529EjrJ |
1 |
|
The document is a final report from 3M Company detailing a longitudinal analysis of serum PFOS and PFOA levels in relation to lipid and hepatic clinical chemistry test results among male employees participating in the company's fluorochemical medical surveillance program conducted in 1994/95, 1997, and 2000.
|
2001 |
AR226-1048
|
qmk6607dG4jEQ8DwYx3MoDJvj |
63 |
|
3M submitted a correction notice to the EPA regarding a TSCA Section 8(e) Supplemental Notice on sulfonate-based fluorochemicals, including an omitted study on selected fluorochemicals in the Decatur, Alabama area, and provided additional analytical reports related to blood serum and liver levels of test materials.
|
2001 |
AR226-1049
|
gbBz7K61xOnYn19kgKxZw0KjJ |
5 |
|
The document is a final report from 3M Company detailing a cross-sectional analysis of serum levels of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) among employees participating in the 2000 medical surveillance program at their Antwerp and Decatur fluorochemical manufacturing plants, focusing on potential correlations with clinical chemistry, thyroid hormone, hemat
|
2001 |
AR226-1047
|
nNNk2NzEX2Y9gdgzNz9j458o8 |
122 |
|
This document reports on a monitoring study conducted by Entrix, Inc. for 3M, which analyzed concentrations of selected fluorochemicals, including PFOS and PFOA, in surface water, sediments, clams, and fish around the 3M facility in Decatur, Alabama, revealing significant variations in PFOS levels near the facility's discharge point.
|
2001 |
AR226-1050
|
KRd9qx6KJkmj71a5GdqXoJogx |
84 |
|
The document discusses the use of liquid chromatography/tandem mass spectrometry to analyze perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) in biota and aqueous samples following a release of firefighting foam containing these perfluorinated surfactants into Etobicoke Creek, Ontario.
|
2001 |
AR226-1059
|
oqp0zeVoyOqYMoXOQ0xgZKn8 |
2 |
|
The document discusses a method developed by researchers from Oregon State University and the University of Toronto for the determination of anionic perfluorinated surfactants, specifically perfluorinated carboxylates and sulfonates, in groundwater using liquid chromatography coupled with electrospray ionization mass spectrometry (LC ESI MS), highlighting the environmental persistence of these compounds and the discontinuation of their production
|
2001 |
AR226-1060
|
NKr2J75bO89ene494vJoKG3D |
2 |
|
The document is a guide developed by the Fluoropolymer Manufacturers Group intended to provide general guidelines for the safe handling of fluoropolymer dispersions, emphasizing that it does not guarantee compliance with regulations or safe operation.
|
2001 |
AR226-1063
|
ymm99K9Xw0QqXJgwBwwrj2nxd |
21 |
|
This document is a cover page for a toxicity study (MIN 252/004312) conducted by a research laboratory, detailing compliance with Good Laboratory Practice standards and including quality assurance statements related to the study.
|
2001 |
AR226-1056
|
vmK9nMwjjNJ6zBky1dq83Lzq |
258 |
|
The document is a final report from 3M Company detailing a cross-sectional analysis of serum levels of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) among employees participating in the 2000 medical surveillance program at their Antwerp and Decatur fluorochemical manufacturing plants, highlighting the demographics and participation rates of the employees involved.
|
2001 |
AR226-1087
|
LJ4ZReDXD8ZLqnaDmK03O3aZb |
122 |
|
The document is a final report from 3M Company detailing a longitudinal analysis of serum levels of Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) in relation to lipid and hepatic clinical chemistry test results among male employees participating in the company's fluorochemical medical surveillance program conducted in 1994/95, 1997, and
|
2001 |
AR226-1088
|
xzxzyDB05Xvq233yprqbaYpKE |
63 |
|
The document is a final summary report of an extended recovery study following a 26-week capsule toxicity study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS) conducted on Cynomolgus monkeys, sponsored by 3M and compliant with EPA Good Laboratory Practice Standards.
|
2001 |
AR226-1102
|
85dqNoVOmoovxmn0Z0dBG3G4a |
23 |
|
The document details a revised soil adsorption study for Perfluorooctanesulfonate (PFOS), indicating its purity of 97.9% and describing the methodology based on OECD 106, including soil characteristics from various locations in Minnesota and North Dakota.
|
2001 |
AR226-1107
|
dn94B0xpjXVXoDZz7qEqG3zpe |
28 |
|
A monitoring study conducted by Entrix, Inc. for 3M assessed the concentrations of selected fluorochemicals, including PFOS and PFOA, in surface water, sediments, clams, and fish in the Decatur, Alabama area, revealing that while the 3M Outfall affected water quality in Bakers Creek, no significant changes were observed at the downstream location, Fox Creek.
|
2001 |
AR226-1109
|
a42DVpQon4kjDyxg03NG9rEVB |
40 |
|
This document details a study on the bioaccumulation of perfluorooctanesulfonate (PFOS) from a 3M production lot in bluegill fish, indicating a purity of 86.9% and outlining the testing methods, conditions, and results related to PFOS exposure and its effects on the fish.
|
2001 |
AR226-1108
|
MJ2Q5yLnKXeXxBKEqvo1JvEGa |
139 |
|
The document is an annual report detailing the activities and progress of the Telomer Research Program grant at the University of Toronto, led by Scott Mabury, focusing on fluorotelomer alcohols (FTOH) research and involving multiple academic collaborators and students.
|
2001 |
AR226-1281
|
LBoL0mY2KboaXk4wDe70qN1d |
19 |
|
This document appears to be a list of various studies and reports related to fluorinated surfactants and PFOA/PFOS, including titles, types, and submission dates to the EPA.
|
2001 |
AR226-1294
|
99maYVjZr7B2RrjNBRyG1X4x7 |
1 |
|
This document is a correspondence regarding a class action lawsuit against E.I. duPont de Nemours and Company related to the contamination of drinking water in Wood County, West Virginia, with ammonium perfluorooctanoate (PFOA).
|
2001 |
AR226-1170
|
VK2m4p0XMVR6Y5nvz861qEJn4 |
4 |
|
The document reports on a range-finding study conducted by E.I. du Pont de Nemours and Company to determine dose levels for a 90-day subchronic toxicity study of 8-2 Telomer B Alcohol in rats, noting no mortality but a significant increase in striated teeth incidence related to the test substance.
|
2001 |
AR226-1339
|
rxRQp64LXQ2XXNwd3Xz6mr6de |
11 |
|
The document reports on a study conducted by Covance Laboratories to evaluate the clastogenic activity of 8-2 Alcohol in male rats, finding no significant increase in micronucleated polychromatic erythrocytes at any tested dose level.
|
2001 |
AR226-1345
|
YMLDVpJ9xnYyXgkVVOgw5y0 |
2 |
|
The document reports on a study conducted by Covance Laboratories to evaluate the mutagenic potential of purified 8-2 alcohol using Salmonella and Escherichia coli strains, finding no significant increase in reverse mutations across the tested strains.
|
2001 |
AR226-1346
|
ZJ8MvEG0R9qneGK3bvv289vMZ |
2 |
|
This document is a letter from 3M Specialty Materials dated January 18, 2001, regarding a supplemental submission related to perfluorooctanesulfonamide (PFOSA) and includes a final report on a toxicokinetic study of PFOSA in rats conducted by 3M's Strategic Toxicology Laboratory.
|
2001 |
AR226-0992
|
NG7LeMg7N8mj47d9bmj856X7b |
3 |
|
This is a letter from Taft, Stettinius & Hollister LLP, dated March 6, 2001, regarding a request for governmental action and intent to sue DuPont over C-8 releases in Wood County, West Virginia, representing the Tennant family in an ongoing lawsuit.
|
2001 |
AR226-1246
|
v1waEkjR5yRN1LGymGDrm37Vm |
957 |
|
The document is a Consent Order issued to E. I. Du Pont de Nemours and Company by the West Virginia Department of Environmental Protection and the Department of Health and Human Resources, requiring actions to assess the impact of ammonium perfluorooctanoate (C8) releases from DuPont's operations on human health and the environment.
|
2001 |
AR226-1171
|
npnMKBGZ4NzeVVBbENd0vvZa8 |
37 |
|
The document is a PowerPoint presentation summarizing EPA activities and issues related to fluorosurfactants, specifically PFOS and PFOA, presented to the Department of Defense to assist in their budget and operational planning for fire fighting activities.
|
2001 |
AR226-0996
|
15bb0eG1dgDnpx9La4a900qvE |
4 |